Provided by Tiger Trade Technology Pte. Ltd.

Capricor Therapeutics

9.47
+0.900010.50%
Post-market: 9.46-0.0101-0.11%19:59 EDT
Volume:20.57M
Turnover:208.71M
Market Cap:550.58M
PE:-3.84
High:10.72
Open:10.03
Low:9.40
Close:8.57
52wk High:40.37
52wk Low:2.96
Shares:58.14M
Float Shares:42.60M
Volume Ratio:8.40
T/O Rate:48.28%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4659
EPS(LYR):-2.2601
ROE:-73.70%
ROA:-33.63%
PB:2.24
PE(LYR):-4.19

Loading ...

Capricor Therapeutics Says Deramiocel BLA PDUFA Target Action Date Set for August 22

Reuters
·
Jun 26

Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review Bla for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

THOMSON REUTERS
·
Jun 26

Capricor Therapeutics - Deramiocel Bla Pdufa Target Action Date Set for August 22, 2026

THOMSON REUTERS
·
Jun 26

Capricor presents five-year data from HOPE-2 open-label extension study

TIPRANKS
·
Jun 26

Capricor Says Deramiocel Meets Primary Endpoint in Hope-3 Phase 3 Duchenne Muscular Dystrophy Trial

Reuters
·
Jun 26

Capricor Therapeutics EVP, General Counsel Karen Krasney Sells 900 Shares for $27,000

Reuters
·
Jun 25

Analysts Offer Insights on Healthcare Companies: Odyssey Therapeutics, Inc. (ODTX), Capricor Therapeutics (CAPR) and Medtronic (MDT)

TIPRANKS
·
Jun 18

Capricor Therapeutics shareholders reject officer exculpation charter amendment at annual meeting

Reuters
·
Jun 09

Capricor Therapeutics to present at Goldman Sachs Global Healthcare Conference

Reuters
·
Jun 08

Why Capricor Therapeutics (CAPR) Is Down 10.8% After FDA Clears Key Deramiocel Inspection Step

Simply Wall St.
·
Jun 07

Capricor publishes investor presentation on deramiocel Duchenne muscular dystrophy program

Reuters
·
May 29

Capricor names Michael Maurer chief commercial officer

Reuters
·
May 29

Capricor Therapeutics files Form 3 for Chief Commercial Officer Michael T. Maurer

Reuters
·
May 29

A Look At Capricor Therapeutics (CAPR) Valuation After Deramiocel Launch Delay And Milestone Cut

Simply Wall St.
·
May 25

Capricor publishes investor presentation on deramiocel Duchenne muscular dystrophy program

Reuters
·
May 21

Capricor Faces Revenue Risk as Dependence on Nippon Shinyaku Puts Deramiocel Commercialization in Jeopardy

TIPRANKS
·
May 15

Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)

TIPRANKS
·
May 15

Assessing Capricor Therapeutics (CAPR) Valuation After Strong Multi Year Gains And Recent Share Price Pullback

Simply Wall St.
·
May 14

Capricor Therapeutics Price Target Maintained With a $60.00/Share by HC Wainwright & Co.

Dow Jones
·
May 13

BRIEF-Capricor Therapeutics Reports First Quarter 2026 Financial Results

Reuters
·
May 13